Optical control of adenosine A₃ receptor function in psoriasis

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Psoriasis is a chronic inflammatory skin condition affecting 2% of the population.
• Current treatments for moderate-to-severe psoriasis cause systemic immunosuppression and side effects.
• The G-protein coupled adenosine A3 receptor (A3R) is a promising therapeutic target for psoriasis.

Purpose of the Study:

• To evaluate the efficacy of a selective A3R agonist (MRS5698) in a mouse model of psoriasis.
• To develop and test the first photosensitive A3R agonist (MRS7344) for targeted psoriasis treatment.

Main Methods:

• Utilized the IL-23 mouse model to simulate psoriasis.
• Administered a selective A3R agonist (MRS5698) to assess its therapeutic potential.
• Developed a photocaged A3R agonist (MRS7344) and evaluated its efficacy using photopharmacology.

Main Results:

• The selective A3R agonist MRS5698 effectively prevented the psoriatic-like phenotype in the IL-23 mouse model.
• The photosensitive A3R agonist MRS7344 also demonstrated efficacy in preventing the psoriatic-like phenotype.
• Photopharmacological application of MRS7344 showed successful site-specific treatment.

Conclusions:

• Selective A3R agonists show therapeutic potential for psoriasis.
• A photosensitive A3R agonist enables non-invasive, light-directed psoriasis treatment.
• This photopharmacological approach offers a feasible strategy for targeted psoriasis therapy.